Antibodies to canine and feline oncostatin M receptor beta and uses thereof

An isolated antibody, or antigen-binding portion thereof that specifically binds to canine or feline Oncostatin M receptor Beta (OSMR-β) or both, comprising a combination of complementary determining region (CDR) sequences selected from the group consisting of:

• 1) 02D09:
• variable heavy (VH)-CDR1 of SEQ ID NO:
• 1
• (DYGMH),
• VH-CDR2 of SEQ ID NO:
• 2 (YISSGSRAVFFADTVKG),
• VH-CDR3 of SEQ ID NO:
• 3 (DRYDGRGFAY),
• variable light (VL)-CDR1 of SEQ ID NO:
• 4
• (RASQSISNNLH),
• VL-CDR2 of SEQ NO:
• 5 (YASQSIS), and
• VL-CDR3 of SEQ ID NO:
• 6 (QQSNSWPLT);
• 2) 09E09:
• VH-CDR1 of SEQ ID NO:
• 7 (SYAMS),
• VH-CDR2 of SEQ ID NO:
• 8 (YISSGGDYIYYADTVKG),
• VH-CDR3 of SEQ ID NO:
• 9 (DPITGTFAY),
• VL-CDR1 of SEQ ID NO:
• 10 (RASQDINNYLN),
• VL-CDR2 of SEQ ID NO:
• 11 (YTSTLHS), and
• VL-CDR3 of SEQ ID NO:
• 12 (QQGNTLPWT);
• 3) 10F07:
• VH-CDR1 of SEQ ID NO:
• 13 (SYAMS),
• VH-CDR2 of SEQ ID NO:
• 14 (YISSGGDYFYYADTVKG),
• VH-CDR3 of SEQ ID NO:
• 15 (DPITGTFAY),
• VL-CDR1 of SEQ ID NO:
• 16 (RASQDITNYLN),
• VL-CDR2 of SEQ ID NO:
• 17 (YTSTLHS), and
• VL-CDR3 of SEQ ID NO:
• 18 (QQGHMLPWT);
• 4) 14C04:
• VH-CDR1 of SEQ ID NO:
• 19 (NYWMN),
• VH-CDR2 of SEQ ID NO:
• 20 (QIYPGHVNTNYNGNFKD),
• VH-CDR3 of SEQ ID NO:
• 21 (SADNSGFVLFAY),
• VL-CDR1 of SEQ ID NO:
• 22 (RASKSVSTSGYSYLH),
• VL-CDR2 of SEQ ID NO:
• 23 (LASNLES), and
• VL-CDR3 of SEQ ID NO:
• 24 (QHSRELPLT);
• 5) 19F07:
• VH-CDR1 of SEQ ID NO:
• 25 (DYYMA),
• VH-CDR2 of SEQ ID NO:
• 26 (NINYDGSSTYYLDSLKS),
• VH-CDR3 of SEQ ID NO:
• 27 (GLTWDFDV),
• VL-CDR1 of SEQ ID NO:
• 28 (KASQDVDTAVA),
• VL-CDR2 of SEQ ID NO:
• 29 (LASTRHT), and
• VL-CDR3 of SEQ ID NO:
• 30 (QQYSRFPLT);
• or
• 6) CDR variants of 1, 2, 3, 4, or 5.